Used in immunotherapy research to modulate T-cell activation by targeting the 4-1BB ligand (TNFSF9), this antibody helps enhance anti-tumor immune responses. It is primarily applied in preclinical studies for cancer immunotherapies, especially in evaluating immune checkpoint pathways. The antibody supports the development of treatments aimed at boosting immune system recognition and destruction of tumor cells. It may also be used as a reference standard in comparative studies of 4-1BB pathway inhibitors or agonists.